drugset / Trial / NCT04790448
Efficacy of VIC Regimen in BRAF Mutant Metastatic Colorectal Cancer
NaSingle-groupOpen-labelTreatment
Summary
This prospective, multicenter, single arm clinical trial was designed to evaluate the efficacy and safety of Vemurafenib in combination with Irinotecan and Cetuximab in the treatment of BRAF V600E-Mutant Metastatic Colorectal Cancer.
Timeline
- Start
- 2020-07-27
- Primary completion
- 2021-12-31
- Completion
- 2021-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cetuximab | Monoclonal antibody | 500 mg/m2 | Intravenous |
| Subject | Irinotecan | Small molecule | 150 mg/m2 | Intravenous |
| Subject | Irinotecan | Small molecule | 180 mg/m2 | Intravenous |
| Subject | Vemurafenib | Small molecule | 480 mg | Oral |
| Subject | Vemurafenib | Small molecule | 720 mg | Oral |
| Subject | Vemurafenib | Small molecule | 960 mg | Oral |